Skip to Content

Generic Probuphine Availability

Probuphine is a brand name of buprenorphine, approved by the FDA in the following formulation(s):

PROBUPHINE (buprenorphine hydrochloride - implant;implantation)

  • Manufacturer: BRAEBURN PHARMS INC
    Approval date: May 26, 2016
    Strength(s): EQ 80MG BASE/IMPLANT [RLD]

Has a generic version of Probuphine been approved?

No. There is currently no therapeutically equivalent version of Probuphine available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Probuphine. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Implantable polymeric device for sustained release of buprenorphine
    Patent 7,736,665
    Issued: June 15, 2010
    Inventor(s): Patel; Rajesh A. & Bucalo; Louis R.
    Assignee(s): Titan Pharmaceuticals, Inc.
    The present invention provides compositions, methods, and kits for treatment of opiate addiction and pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time. Buprenorphine is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with buprenorphine.
    Patent expiration dates:
    • April 25, 2024
      ✓ 
      Patent use: FOR OPIOID DEPENDENCE

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • May 26, 2019 - NEW PRODUCT

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide